Ascendis Pharma (ASND) said its supplemental biologics license application for TransCon hGH as therapy for adult growth hormone deficiency was accepted for review by the US Food and Drug Administration.
The FDA has set a July 27 review deadline, the company said Thursday in a statement.
The supplemental application is based on the results of a phase 3 trial that evaluated 259 adults with growth hormone deficiency, and TransCon hGH was found to be "generally safe and well tolerated," Ascendis said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。